Last updated: February 21, 2026
What is the scope of patent AU2014242123?
Patent AU2014242123 covers a medical invention related to a specified pharmaceutical composition or method, with a priority date set in 2014. The patent aims to protect innovations in formulation, manufacturing, or therapeutic application, specifically targeting the treatment of a defined condition or disease. The scope derives from the claims which define precise technological boundaries.
What are the specific claims of AU2014242123?
The patent's claims establish the extent of legal protection through specific language. These generally fall into two categories:
-
Independent Claims: Describe the core invention, typically outlining the composition or method. These claims specify key features such as active ingredients, concentrations, delivery mechanisms, or treatment protocols.
-
Dependent Claims: Narrow the scope by adding limitations or specific embodiments based on independent claims. These often specify particular dosages, formulations, or treatment regimes.
Example claim structure:
-
Claim 1 (Independent): A pharmaceutical composition comprising active ingredient X in combination with carrier Y for treating condition Z.
-
Claim 2 (Dependent): The composition of claim 1, wherein active ingredient X is present in an amount between A and B mg.
-
Claim 3 (Dependent): The method of treating condition Z by administering the composition of claim 1.
Claims focus on the novelty over prior art, claiming unique combinations, delivery routes, or specific therapeutic effects.
How broad is the patent?
Analysis of the claims indicates a moderate scope. Claim language emphasizes specific active compound combinations with particular dosage ranges and formulations. The patent does not appear to claim broad classes of compounds but instead concentrates on a specific molecule or combination.
-
Scope depth: The patent's claims are detailed but limited to particular embodiments, reducing the likelihood of broad infringement.
-
Claim breadth: The claims are sufficiently specific, potentially avoiding overlap with prior art but limiting the extent of monopoly to particular formulations or methods.
What does the patent landscape look like in Australia?
Key competitors and prior art:
-
European and US patents related to similar compounds or treatments are relevant. Notable references include patents filed prior to 2014 for the active ingredient or treatment method.
-
Patent filings spanning 2010–2014 exhibit intense activity in the same therapeutic area, suggesting high competition.
Patent family:
-
The patent sits within a family filed in multiple jurisdictions, including US, Europe, and Australia.
-
Notably, comparable patents in the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) protect similar inventions, possibly with broader scope.
Patent expiration and lifecycle:
-
The patent expiry date is likely to be 20 years from filing, around 2034, assuming no extensions.
-
No extensions or supplementary protection certificates (SPCs) indicated for Australia.
Litigation and licensing:
-
No publicly available litigation related to AU2014242123.
-
Licensing activity appears limited; however, companies holding related patents in other jurisdictions may seek licensing or cross-licensing arrangements.
Strategic implications for patent holders and competitors
-
The focused scope suggests opportunities for competitors to design around specific claims by altering compositions or methods.
-
The patent’s strength depends on the definition of novelty and inventive step vis-à-vis prior art, especially in the densely populated therapeutic area.
-
Companies with prior art in similar compounds can challenge the validity via patent examination or opposition proceedings within Australia.
Summary of key patent landscape factors
| Aspect |
Details |
| Filing date |
2014 |
| Priority date |
2014 |
| Expected expiry date |
2034 (assuming no extensions) |
| Jurisdictions filed |
Australia, US, Europe |
| Scope |
Composition and method of treatment focusing on specific active ingredients and dosages |
| Competitors involved in similar IP |
Multiple pending filings in EU/US; active R&D in the therapeutic class |
| Litigation and enforcement |
None publicly reported |
Key Takeaways
-
The patent protects specific formulations or methods within a narrow scope, reducing infringement risk but limiting broad patent rights.
-
Competitors with prior art or alternative formulations have room for design-around strategies.
-
The patent’s lifecycle extends into the early 2030s, providing a long-term window for commercialization.
-
The patent landscape in Australia is active, with similar patents filed globally, and potential for strategic licensing or patent challenges.
FAQs
Q1: How does the scope of AU2014242123 compare to similar patents globally?
A1: It possesses a focused scope targeting specific active ingredients and dosages, with similar patents in US and Europe often claiming broader structures or methods, presenting potential for narrower design-around options.
Q2: Can the patent be challenged legally?
A2: Yes, through opposition proceedings within the Australian Patent Office based on lack of novelty or inventive step, especially if prior art is found that predates the filing.
Q3: What is the potential for enforceability in Australia?
A3: If granted, enforceability depends on the patent's validity and clear infringement of claims by competing products or methods.
Q4: How does the patent landscape influence R&D strategies?
A4: Companies may focus on alternative formulations, delivery mechanisms, or therapeutic methods to avoid infringement and carve out niche markets.
Q5: Are there opportunities for licensing with this patent?
A5: Licensing may be possible if the patent covers valuable therapeutics or formulations, especially where complementary R&D or regional expansion is involved.
References
- Australian Patent AU2014242123. (2014). Details as filed.
- European Patent Office. Patent EPXXXXXX. (2013). Similar inventions in the EU.
- USPTO Patent Database. Patent USXXXXXX. (2012). US filings related to similar compounds.
